www.fdanews.com/articles/149673-astex-pharma-ends-development-of-lung-cancer-drug
Astex Pharma Ends Development of Lung Cancer Drug
September 24, 2012
Cancer drugmaker Astex Pharmaceuticals said it would discontinue the development of its experimental small-cell lung cancer drug, Amuvatinib, as the drug failed to achieve a high enough response rate in patients in a mid-stage study.
Reuters
Reuters